Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.

Thomas A, Walpurgis K, Tretzel L, Brinkkötter P, Fichant E, Delahaut P, Schänzer W, Thevis M

Drug testing and analysis18 Sept 2015Cited by 31 (Europe PMC)

PMID26382721DOI10.1002/dta.1868PepBankPUB-26382721

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of Sermorelin aloneOther designOther
An immunoaffinity LC-HRMS/MS method for peptides above 2 kDa, including sermorelin, had recovery of 11-69%.
In plain wordsA lab method recovered 11 to 69 percent of the target peptides, which include sermorelin.
Peptide
Sermorelin
Outcome
Not applicableRecovery
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Recovery
11 to 69%
target peptides
Source sentences
Summary
recovery (11-69%), linearity, imprecision (<25%), limit of detection (5-100 pg in urine, 0.1-2 ng in plasma), and ion suppression.
1 context sentence(design, population, supporting numbers)
Summary · context
Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-2638272101
02LabNot a test of Sermorelin aloneOther designOther
The method had imprecision below 25%.
In plain wordsThe lab method gave repeatable results, with variation below 25 percent.
Peptide
Sermorelin
Outcome
Not applicableImprecision
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Imprecision
< 25%
target peptides
Source sentences
Summary
imprecision (<25%), limit of detection (5-100 pg in urine, 0.1-2 ng in plasma), and ion suppression.
1 context sentence(design, population, supporting numbers)
Summary · context
Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-2638272102
03LabNot a test of Sermorelin aloneOther designOther
The method had limits of detection of 5-100 pg in urine for the target peptides, which include sermorelin.
In plain wordsThe lab method detected the target peptides, including sermorelin, in urine at 5 to 100 pg.
Peptide
Sermorelin
Outcome
Not applicableLimit of detection in urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
5 to 100 pg
target peptides in urine
Source sentences
Summary
limit of detection (5-100 pg in urine, 0.1-2 ng in plasma), and ion suppression.
1 context sentence(design, population, supporting numbers)
Summary · context
Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-2638272103
04LabNot a test of Sermorelin aloneOther designOther
The method had limits of detection of 0.1-2 ng in plasma for the target peptides, which include sermorelin.
In plain wordsThe lab method detected the target peptides, including sermorelin, in plasma at 0.1 to 2 ng.
Peptide
Sermorelin
Outcome
Not applicableLimit of detection in plasma
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
LOD
0.1 to 2 ng
target peptides in plasma
Source sentences
Summary
0.1-2 ng in plasma), and ion suppression.
1 context sentence(design, population, supporting numbers)
Summary · context
Such peptides have been used to manipulate several potential performance-enhancing processes in the athlete's body and include for example growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin)
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-2638272104
05LabNot a test of MGF / PEG-MGF aloneOther designOther
An immunoaffinity and LC-HRMS/MS method for peptides, including MGF forms, was applicable to blood and urine samples.
In plain wordsIn lab tests, the method worked on both blood and urine samples for peptide drugs, including MGF forms.
Peptide
MGF / PEG-MGF
Outcome
Not applicableApplicability of the test method to blood and urine
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Source sentences
Summary
The method was shown to be applicable to blood and urine samples, which represent the most common doping control specimens.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-2638272105
06LabNot a test of MGF / PEG-MGF aloneOther designOther
The method was validated for specificity, recovery (11-69%), linearity, imprecision (<25%), limit of detection and ion suppression across the target peptides, including MGF forms.
In plain wordsIn lab tests, the method was validated for the peptides it covers, including MGF forms, with recovery of 11-69%.
Peptide
MGF / PEG-MGF
Outcome
Not applicableValidation parameters of the test method
Study
n: not reported in source
Outcome group
Analytical methods and detection · Pharmacology
Measurements
Recovery
11 to 69%
target analytes
Imprecision
< 25%
target analytes
Limit of detection
5 to 100 pg
urine
Limit of detection
0.1 to 2 ng
plasma
Source sentences
Summary
The method was validated considering the parameters specificity, recovery (11-69%), linearity, imprecision (<25%), limit of detection (5-100 pg in urine, 0.1-2 ng in plasma), and ion suppression.
In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.
Report a problemFND-2638272106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 25 to 48Current
28 Oct 2026, 02:04 UTC
The same notice was added 24 times, first on 13 Oct 2026, 21:43 UTC. The status did not change between them.
Study results updated
Version 24
13 Oct 2026, 16:31 UTC
Study data updated · source update from Europe PMC
Versions 4 to 23
13 Oct 2026, 14:22 UTC
The same notice was added 20 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Versions 2 to 3
9 Oct 2026, 03:13 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.